(Q46573303)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

main subject

phase III clinical trial

0 references

1 reference

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Miguel Martín

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Alvaro Rodríguez-Lescure

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Amparo Ruiz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Emilio Alba

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Lourdes Calvo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Manuel Ruiz-Borrego

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Blanca Munárriz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

César A Rodríguez

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Carmen Crespo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

José Antonio López García-Asenjo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

María Dolores Guitián

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Sergio Almenar

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jesús Fernando González-Palacios

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Francisco Vera

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

José Palacios

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Manuel Ramos

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jose Manuel Gracia Marco

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Ana Lluch

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Isabel Alvarez

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Miguel Angel Seguí

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

José Ignacio Mayordomo

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Antonio Antón

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

José Manuel Baena

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Arrate Plazaola

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Alfonso Modolell

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Amadeu Pelegrí

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jose Ramón Mel

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Enrique Aranda

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Encarna Adrover

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

José Valero Alvarez

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

José Luis García Puche

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Pedro Sánchez-Rovira

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Sonia Gonzalez

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

José Manuel López-Vega

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

GEICAM 9906 Study Investigators

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

27 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

805-814

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18505968%20AND%20SRC:MED&resulttype=core&format=json

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Molecular biology of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN151